Treatment options for small cell lung cancer - do we have more choice? Br J Cancer. 2010; 102 (4):629–38. doi: 10.1038/sj.bjc.6605527. [ Cross Ref ]Puglisi M, Dolly S, Faria A, Myerson J, Popat S, O'Brien M. Treatment options for small cell lung cancer—do we have more ...
Small-cell lung cancer spreads quickly. From 67%-75% of people who develop small cell lung cancerwill have spread the SCLC outside of the lung to other parts of the body at the time of initial diagnosis. Small-cell lung cancer responds well to chemotherapy (using medications to kill cancer...
Traditionally, patients with small-cell lung cancer (SCLC), a malignancy with a dismal prognosis, have had limited treatment options. Over the past few years, advances in the molecular characterization of SCLC have revealed novel therapeutic targets. The authors of this Review summarize these finding...
Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more than two decades without clinical progress, the addition of programmed cell death protein 1 axis blockade to platinum-based chemotherapy has demonstrated sustained overall survival benefit and represents the current...
Small-cell lung cancer (SCLC) is a deadly cancer associated with smoke exposure that has neuroendocrine (NE) cell properties and is pathologically, molecularly, biologically and clinically very different from other lung cancers. While most patients with SCLC respond initially to cytotoxic therapy, almo...
Figure 2. Phase II and III trials assessing an immune-chemotherapy strategy in the first-line setting in extensive-disease (ED) small cell lung cancer (SCLC) with outcomes. CI, confidence interval; CR, complete response; PR, partial response; CT, chemotherapy; HR, hazard ratio; OS, overall...
Small cell lung cancer is characterized by early metastases and rapid growth. While initially very responsive to both chemotherapy and radiation therapy, the majority of patients will have recurrent disease or become refractory to treatment. The 5-year survival of patients with small cell lung...
KEYTRUDA may be used in combination with chemotherapy that contains platinum and another chemotherapy medicine before surgery when you have early-stage non–small cell lung cancer, which can be removed by surgery, and then continued alone after surgery to help prevent your lung cancer from coming ...
作者: Felip,E. 展开 摘要: The article presents clinical recommendations from the European Society for Medical Oncology (ESMO) for the diagnosis, treatment and follow-up of small-cell lung cancer. Its pathological diagnosis is made according to the World Health Organization classification. Staging...
Small cell lung cancer (SCLC) is one of a pathological type of lung cancer, and it is characterized by invasiveness, high malignancy and refractoriness. The mortality rate of SCLC is significantly higher than other types of lung cancer, and the treatment options for SCLC patients are limited. ...